Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
HPV16 E7 (86-93) acetate
Catalog No. TP1554L
HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $129 | In Stock | |
| 5 mg | $265 | In Stock | |
| 10 mg | $377 | In Stock | |
| 25 mg | $633 | In Stock | |
| 50 mg | $883 | In Stock | |
| 100 mg | $1,230 | In Stock | |
| 500 mg | $2,470 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreProduct Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas. |
| In vitro | HPV16 E7 peptide-loaded autologous dendritic cells stimulate a specific cytotoxic CD8+ T-cell response[1]. HPV16 E7 (86-93) acetate specific T cells expand upon in vitro stimulation with cognate peptide-pulsed dendritic cells. HPV16 E7 (86-93) acetate specific T cells are reactive against peptide-pulsed targets. HPV16 E7 (86-93) acetate specific E711-20 T cells are reactive against HPV16 E7 expressing CaSki cell line. Precursor T cells specific for HPV16 E7 (86-93) acetate differentiates into HPV specific effector cells in vitro[2]. |
| In vivo | HPV16 E7 (86-93) acetate in IVS culture has specific T cell expansion without recognizing naturally HPV16 E7 expressing cell line CaSki. HPV16 E7 (86-93) acetate has similar observations in transgenic mice. HPV16 E7 (86-93) acetate induces cytotoxic T lymphocyte responses when loaded on the antigen presenting HLA class I molecules[2]. |
| Alias | HPV16 E7 (86-93) acetate(160212-93-1 Free base) |
| Molecular Weight | 875.08 |
| Formula | C39H70N8O12S |
| Cas No. |
| Storage | keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.